Sanofi’s Rilzabrutinib & Belumosudil Among Seven Drugs Facing EMA Oral Explanations

 
• By Vibha Sharma
  
White paper with pen in meeting room.
The EMA is scheduled to hear oral arguments from sponsors of seven medicines (Shutterstock)

More from EU CHMP

More from Product Reviews